title: Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.
abstract: Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies-informing on its efficacy, use, and adverse features-and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008-focusing on efficacy, side effects, and utility.
authors.affiliation: Regional Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK, andrew.ustianowski@pat.nhs.uk.
authors.forename: Andrew
authors.initials: A
authors.lastname: Ustianowski
authors.forename: Joop E
authors.initials: JE
authors.lastname: Arends